WEKO3
インデックスリンク
アイテム
Development of combinatorial immunotherapy for patients with advanced gastric cancer from the perspective of immunosuppressive mechanisms in the tumor microenvironment
https://fmu.repo.nii.ac.jp/records/2002537
https://fmu.repo.nii.ac.jp/records/200253756e2f1d2-a87e-418e-a132-2a602aa2d67b
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
FksmJMedSci_72_p1.pdf (750.5 KB)
|
.png)
|
| Item type | デフォルトアイテムタイプ（フル）fmu(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2026-01-07 | |||||||||
| タイトル | ||||||||||
| タイトル | Development of combinatorial immunotherapy for patients with advanced gastric cancer from the perspective of immunosuppressive mechanisms in the tumor microenvironment | |||||||||
| 言語 | en | |||||||||
| 作成者 |
Mimura, Kosaku
× Mimura, Kosaku
× Kono, Koji
|
|||||||||
| アクセス権 | ||||||||||
| アクセス権 | open access | |||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||
| 権利情報 | ||||||||||
| 権利情報Resource | https://creativecommons.org/licenses/by-nc-sa/4.0/ | |||||||||
| 権利情報 | © 2026 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | Combinatorial immunotherapy using anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) is being developed to overcome the limited efficacy of monotherapy with anti-PD-1 mAb for patients with advanced gastric cancer (GC). Anti-PD-1 mAb exhibits clinical efficacy by enhancing the function of cytotoxic T lymphocyte (CTL) through the inhibition of the PD-1 pathway;however, there are various immunosuppressive mechanisms that inhibit CTL function, as well as the PD-1 pathway in the tumor microenvironment (TME). Immune suppressive cells and expression of the inhibitory immune checkpoint molecules are included as main inhibitory mechanisms against CTL in the TME. On the other hand, increasing the number of CTLs enhances the efficacy of anti-PD-1 mAb, and immunogenic tumor cell death (ICD) is crucial to induce CTL through the activation of the cancer immunity cycle. In the present review, we discuss the therapeutic potential of developing combinatorial immunotherapy focusing on the inhibitory immune checkpoint molecules and immune suppressive cells in the TME, as well as on the ICD induced by radiotherapy for patients with advanced GC. | |||||||||
| 出版者 | ||||||||||
| 出版者 | The Fukushima Society of Medical Science | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| 書誌情報 |
en : Fukushima journal of medical science 巻 72, 号 1, p. 1-14, 発行日 2026 |
|||||||||
| 関連情報 | ||||||||||
| 関連タイプ | isIdenticalTo | |||||||||
| 識別子タイプ | DOI | |||||||||
| 関連識別子 | https://doi.org/10.5387/fms.25-00009 | |||||||||
| 関連情報 | ||||||||||
| 識別子タイプ | PMID | |||||||||
| 関連識別子 | 40903269 | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||
| 資源タイプ | journal article | |||||||||
| 出版タイプ | ||||||||||
| 出版タイプ | VoR | |||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||
| 収録物識別子 | ||||||||||
| 収録物識別子タイプ | PISSN | |||||||||
| 収録物識別子 | 0016-2590 | |||||||||
| 収録物識別子 | ||||||||||
| 収録物識別子タイプ | EISSN | |||||||||
| 収録物識別子 | 2185-4610 | |||||||||
| 収録物識別子 | ||||||||||
| 収録物識別子タイプ | NCID | |||||||||
| 収録物識別子 | AA0065246X | |||||||||
| 主題 | ||||||||||
| 主題Scheme | MeSH | |||||||||
| 主題 | Humans | |||||||||
| 主題 | ||||||||||
| 主題Scheme | MeSH | |||||||||
| 主題 | Stomach Neoplasms | |||||||||
| 主題 | ||||||||||
| 主題Scheme | MeSH | |||||||||
| 主題 | Tumor Microenvironment | |||||||||
| 主題 | ||||||||||
| 主題Scheme | MeSH | |||||||||
| 主題 | Immunotherapy | |||||||||
| 主題 | ||||||||||
| 主題Scheme | MeSH | |||||||||
| 主題 | T-Lymphocytes, Cytotoxic | |||||||||
| 主題 | ||||||||||
| 主題Scheme | MeSH | |||||||||
| 主題 | Programmed Cell Death 1 Receptor | |||||||||
| 主題 | ||||||||||
| 主題Scheme | MeSH | |||||||||
| 主題 | Antibodies, Monoclonal | |||||||||
